CDDD11-8 / University of South Australia - LARVOL DELTA

Selective inhibition of CDK9 in triple negative breast cancer. (PubMed, Oncogene) - "Orally administered CDDD11-8 also inhibited growth of mammary intraductal TNBC xenograft tumours with no overt toxicity in vivo (mice) or ex vivo (human breast tissues). In conclusion, our studies indicate that CDK9 is a viable therapeutic target in TNBC and that CDDD11-8, a novel selective CDK9 inhibitor, has efficacy in TNBC without apparent toxicity to normal tissues."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CDK9 • MYC